![]() |
|
|
Vol. 296, Issue 2, 473-477, February 2001
Cardiovascular Research, Starr Academic Center for Cardiac Surgery,
Providence Heart Institute, St. Vincent Hospital, Portland, Oregon
(M.-H.L., S.F., A.F., G.-W.H); Cardiovascular Research, Genentech, Inc.
San Francisco, California (H.-K.J, T.F.Z, S.B.); and Cardiovascular
Surgical Research Laboratory, Department of Surgery, The Chinese
University of Hong Kong, Hong Kong SAR, China (Q.Y., A.P.C.Y.,
G.-W.H.)
The vasodilatory effect of VEGF has not been characterized in the
setting of hypertension. This study investigated the in vitro
vasorelaxant effects of VEGF in organ chambers in the aorta of the
adult (12-week-old) spontaneously hypertensive rats (SHR), young
(4-week-old) SHR without hypertension, and age-matched Wistar-Kyoto (WKY) rats compared with acetylcholine (ACh). Cumulative
concentration-relaxation curves were established for VEGF
(~10
12-10
8.5 M) and ACh
(~10
10-10
5 M) in U46619
(10
8 M)-induced contraction. VEGF induced
endothelium-dependent relaxation that was significantly reduced in the
adult SHR compared with the age-matched WKY control (87.8 ± 2.8 versus 61.4 ± 8.6%, P = 0.01). These
responses were significantly attenuated by pretreatment with
N
-nitro-L-arginine
(L-NNA, 300 µM) alone (SHR: 25.1 ± 1.9%; WKY: 21.0 ± 2.6%; P = 0.01) or indomethacin (7 µM) + L-NNA (SHR: 30.2 ± 2.1%; WKY: 35.0 ± 2.9%; P = 0.01). Further addition of oxyhemoglobin (20 µM) abolished the residual relaxation and reduced the relaxation induced by nitroglycerin. ACh induced similar responses to VEGF. In
contrast, pretreatment with indomethacin alone enhanced VEGF- or
ACh-induced relaxations and the effect was greater in the adult SHR
than in WKY rats. In contrast to the adult SHR versus WKY rats, there
were no significant differences of VEGF- or ACh-induced relaxations
between young SHR and WKY rats. The results demonstrate that VEGF
induces endothelium- or nitric oxide-dependent relaxation, which is
blunted in the adult SHR. The mechanism of this impairment may be
related to decreased release of NO although increased release of
contracting factors from the dysfunctional endothelium may also be involved.
This article has been cited by other articles:
![]() |
P. Brownbill, G. C. McKeeman, J. C. Brockelsby, I. P. Crocker, and C. P. Sibley Vasoactive and Permeability Effects of Vascular Endothelial Growth Factor-165 in the Term in Vitro Dually Perfused Human Placental Lobule Endocrinology, October 1, 2007; 148(10): 4734 - 4744. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Li, A. K. Ogasawara, R. Yang, W. Wei, G.-W. He, T. F. Zioncheck, S. Bunting, A. M. de Vos, and H. Jin KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF Hypertension, June 1, 2002; 39(6): 1095 - 1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Liu, H. Jin, H. S. Floten, Z. Ren, A. P.C. Yim, and G.-W. He Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery Ann. Thorac. Surg., March 1, 2002; 73(3): 819 - 824. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Yang, A. K. Ogasawara, T. F. Zioncheck, Z. Ren, G.-W. He, G. G. DeGuzman, N. Pelletier, B.-Q. Shen, S. Bunting, and H. Jin Exaggerated Hypotensive Effect of Vascular Endothelial Growth Factor in Spontaneously Hypertensive Rats Hypertension, March 1, 2002; 39(3): 815 - 820. [Abstract] [Full Text] [PDF] |
||||